Ian Chau, ASCO 2021: First Results of the Phase III CheckMate 648 Trial
Dr Ian Chau (Royal Marsden Hospital, London, UK) joins us at ASCO 2021 to discuss the pivotal first results of the global phase III CheckMate 648 trial, which revealed first-line nivolumab regimens improve survival in esophageal squamous cell carcinoma.
The abstract (LBA4001) ‘Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study’ was presented at the 2021 ASCO Annual Meeting.
DOI: 10.1200/JCO.2021.39.15_suppl.LBA4001 Journal of Clinical Oncology 39, no. 18_suppl
Clinical Trials Reference number: NCT03143153
Questions
- What are the limitations of current first-line treatments for advanced esophageal squamous cell carcinoma? (00:12-00:56)
- What were the aims, design and eligibility criteria of the Checkmate 648 study? (00:56-02:13)
- What were the overall and progression-free survival outcomes, and how do these compare to those seen previously? (02:13-05:47)
- What were the safety profiles of the two combined treatments? (05:47-06:37)
- When these treatments become available, what factors should influence the choice of nivolumab plus chemotherapy or ipilimumab? (06:37-08:37)
Disclosures: Ian Chau is a member of the advisory board for Eli-Lilly, Bristol Meyers Squibb, MSD, Bayer, Roche, Merck-Serono, Five Prime Therapeutics, Astra-Zeneca, OncXerna, Pierre Fabre, Boehringer Ingelheim, Incyte, Astella, GSK, Sotio and Eisai. He has received research funding from Eli-Lilly and Janssen-Cilag and honorarium from Eli-Lilly, Eisai and Servier.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2021 ASCO Annual Meeting.
